{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:20:49Z","timestamp":1788675649369,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jaad.2019.05.065","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T21:00:09Z","timestamp":1559077209000},"page":"45-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: A systematic review"],"prefix":"10.1016","volume":"82","author":[{"given":"Asma","family":"Amir Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth K.","family":"Seng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Lowes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2019.05.065_bib1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/postgradmedj-2013-131994","article-title":"Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease","volume":"90","author":"Dufour","year":"2014","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jaad.2019.05.065_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40257-014-0105-5","article-title":"Quality-of-life impairment in patients with hidradenitis suppurativa: a Canadian study","volume":"16","author":"Alavi","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2019.05.065_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.det.2015.08.002","article-title":"Prevalence, risk factors, and comorbidities of hidradenitis suppurativa","volume":"34","author":"Miller","year":"2016","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2019.05.065_bib4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaad.2017.02.005","article-title":"Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis","volume":"77","author":"Garg","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.05.065_bib5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/bjd.16101","article-title":"Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa","volume":"178","author":"Ingram","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.05.065_bib6","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamadermatol.2017.0201","article-title":"Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States","volume":"153","author":"Garg","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2019.05.065_bib7","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/bjd.14418","article-title":"Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality","volume":"174","author":"Ingram","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.05.065_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/exd.13158","article-title":"Using the placebo effect: how expectations and learned immune function can optimize dermatological treatments","volume":"26","author":"Evers","year":"2017","journal-title":"Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.05.065_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa","volume":"63","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.05.065_bib10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2133.2011.10339.x","article-title":"A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa","volume":"165","author":"Miller","year":"2011","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2019.05.065_bib11","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2019.05.065_bib12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2019.05.065_bib13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.05.065_bib14","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 Targeting IL-1\u03b1 moderate to severe hidradenitis suppurativa non eligible for adalimumab: a randomized study","volume":"138","author":"Kanni","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2019.05.065_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1365-2133.2003.05390.x","article-title":"Suggestions for\u00a0uniform outcome variables when reporting treatment effects in hidradenitis suppurativa","volume":"149","author":"Sartorius","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.05.065_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0304-3959(03)00176-3","article-title":"What decline in pain intensity is meaningful to patients with acute pain?","volume":"105","author":"Cepeda","year":"2003","journal-title":"Pain"},{"issue":"6","key":"10.1016\/j.jaad.2019.05.065_bib17","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaad.2018.05.015","article-title":"Adalimumab alleviates skin pain in patients with moderate to severe hidradenitis suppurativa: secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials","volume":"79","author":"Kimball","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.05.065_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2019.05.065_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2133.2011.10583.x","article-title":"Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials","volume":"166","author":"Reich","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.05.065_bib20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaad.2019.05.065_bib21","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2019.05.065_bib22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2019.05.065_bib23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Thaci","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2019.05.065_bib24","series-title":"Persuasion & Healing: A Comparative Study of Psychotherapy","author":"Jerome","year":"1991"},{"key":"10.1016\/j.jaad.2019.05.065_bib25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nrn1705","article-title":"Placebos and painkillers: is mind as real as matter?","volume":"6","author":"Colloca","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.jaad.2019.05.065_bib26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0304-3959(00)00486-3","article-title":"Response variability to analgesics: a role for non-specific activation of endogenous opioids","volume":"90","author":"Amanzio","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.jaad.2019.05.065_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev.pharmtox.48.113006.094711","article-title":"Mechanisms of placebo and placebo-related effects across diseases and treatments","volume":"48","author":"Benedetti","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jaad.2019.05.065_bib28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jclinepi.2013.08.015","article-title":"Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects","volume":"67","author":"McCambridge","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaad.2019.05.065_bib29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0738-081X(98)00061-3","article-title":"Placebo therapy in dermatology","volume":"17","author":"Barfod","year":"1999","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2019.05.065_bib30","first-page":"203","article-title":"Psychodermatology: a guide to understanding common psychocutaneous disorders","volume":"9","author":"Jafferany","year":"2007","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1016\/j.jaad.2019.05.065_bib31","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(00)04169-6","article-title":"Influence of context effects on health outcomes: a systematic review","volume":"357","author":"Di Blasi","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2019.05.065_bib32","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1001\/jama.287.14.1840","article-title":"Placebo response in studies of major depression: variable, substantial, and growing","volume":"287","author":"Walsh","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2019.05.065_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2288-5-26","article-title":"The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials \u2013 a secondary analysis","volume":"5","author":"Walach","year":"2005","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.jaad.2019.05.065_bib34","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.16672","article-title":"A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.05.065_bib35","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2016.05.009","article-title":"Color Doppler ultrasound assessment of morphology and types of fistulous tracts in hidradenitis suppurativa (HS)","volume":"75","author":"Wortsman","year":"2016","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219308692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219308692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:52:34Z","timestamp":1759272754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219308692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0190962219308692"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.05.065","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.05.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}